Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
收藏DataCite Commons2025-07-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008979/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a
week to insulin glargine taken once daily in participants with type 2 diabetes and increased
cardiovascular risk. The study will last about 108 weeks and may include up to 30 visits.
提供机构：
Vivli
创建时间：
2023-05-26
